Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
OKYO Pharma is a biotechnology business based in the US. OKYO Pharma stocks (OKYO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.07 – a decrease of 2.33% over the previous week. OKYO Pharma employs 6 staff and has a market cap (total outstanding stock value) of $41.8 million.
|Latest market close||$2.10|
|52-week range||$1.92 - $6.11|
|50-day moving average||$2.51|
|200-day moving average||$2.51|
|Wall St. target price||N/A|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.01|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-06-21)||-2.33%|
|1 month (2022-05-27)||3.45%|
|3 months (2022-03-24)||N/A|
|6 months (2021-12-24)||N/A|
|1 year (2021-06-24)||N/A|
|2 years (2020-06-24)||N/A|
|3 years (2019-06-24)||N/A|
|5 years (2017-06-24)||N/A|
|Gross profit TTM||$-1,987,367|
|Return on assets TTM||-56.73%|
|Return on equity TTM||-94.71%|
|Market capitalisation||$41.8 million|
TTM: trailing 12 months
We're not expecting OKYO Pharma to pay a dividend over the next 12 months.
Over the last 12 months, OKYO Pharma's shares have ranged in value from as little as $1.92 up to $6.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OKYO Pharma's is 0.2697. This would suggest that OKYO Pharma's shares are less volatile than average (for this exchange).
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. .
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.Read more…
Here are some investment ideas that could do well despite rising interest rates.Read more…
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Everything we know about the Onfolio Holdings IPO plus information on how to buy in.
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.